Deepika Jalota Biography and Net Worth

Chief Development Officer of PMV Pharmaceuticals

Dr. Jalota has over 25 years of experience in the life sciences industry with a focus in oncology. Since joining PMV Pharma in 2019, Dr. Jalota has taken on progressively greater responsibilities and now serves as the Chief Development Officer. Prior to joining PMV Pharma, Dr. Jalota was Vice President, Head of Global Regulatory Strategy, Oncology I at Bayer HealthCare Pharmaceuticals where she was responsible for overseeing the development of global regulatory strategies for several early and late stage oncology projects, including Xofigo®, VITRAKVI® and Nubeqa®. From 2014-2016 at Bayer, she was responsible for overseeing the development of global regulatory strategies in Ophthalmology and Dermatology, including Eylea®.

Prior to working at Bayer for 12 years, Dr. Jalota was employed with Sanofi-Aventis, Forest Laboratories and Procter and Gamble Pharmaceuticals within various roles across drug development.

Dr. Jalota received her Pharm.D. from University of Florida, College of Pharmacy, and her B.S. in Pharmacy from Rutgers University, Ernest Mario School of Pharmacy.

What is Deepika Jalota's net worth?: The estimated net worth of Deepika Jalota is at least $131.34 thousand as of July 1st, 2025. Dr. Jalota owns 89,959 shares of PMV Pharmaceuticals stock worth more than $131,340 as of September 18th. This net worth evaluation does not reflect any other assets that Dr. Jalota may own. Learn More about Deepika Jalota's net worth.
How do I contact Deepika Jalota?: The corporate mailing address for Dr. Jalota and other PMV Pharmaceuticals executives is 400 Alexander Park Drive, Suite 301, Princeton, NJ, 08540. PMV Pharmaceuticals can also be reached via phone at 609-642-6670 and via email at [email protected]. Learn More on Deepika Jalota's contact information.
Has Deepika Jalota been buying or selling shares of PMV Pharmaceuticals?: Deepika Jalota has not been actively trading shares of PMV Pharmaceuticals within the last three months. Most recently, Deepika Jalota sold 33,065 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $1.06, for a transaction totalling $35,048.90. Following the completion of the sale, the insider now directly owns 89,959 shares of the company's stock, valued at $95,356.54. Learn More on Deepika Jalota's trading history.
Who are PMV Pharmaceuticals' active insiders?: PMV Pharmaceuticals' insider roster includes Leila Alland (Insider), Richard Heyman (Director), Deepika Jalota (Chief Development Officer), Winston Kung (CFO), Arnold Levine (Director), David Mack (CEO), and Thilo Schroeder (Director). Learn More on PMV Pharmaceuticals' active insiders.
Are insiders buying or selling shares of PMV Pharmaceuticals?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 1,000,000 shares worth more than $1,520,000.00. The most recent insider tranaction occured on October, 23rd when Major Shareholder Orbimed Advisors Llc sold 1,000,000 shares worth more than $1,520,000.00. Insiders at PMV Pharmaceuticals own 10.2% of the company. Learn More about insider trades at PMV Pharmaceuticals.
Information on this page was last updated on 10/23/2025.

Deepika Jalota Insider Trading History at PMV Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2025	Sell	33,065	$1.06	$35,048.90	89,959
9/11/2024	Sell	7,218	$1.50	$10,827.00	118,283
9/15/2023	Sell	4,104	$6.62	$27,168.48	29,946

Deepika Jalota Buying and Selling Activity at PMV Pharmaceuticals

PMV Pharmaceuticals Company Overview

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Today's Range

Now: $1.45

$1.43

$1.46

50 Day Range

MA: $1.28

$1.07

$1.46

2 Week Range

Now: $1.45

$1.02

$1.88

Volume

18,102 shs

Average Volume

491,343 shs

Market Capitalization

$77.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37